



May 30, 2023

The Manger - Listing **BSE Limited**Corporate Relationship Dept., 1<sup>st</sup> Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,

Mumbai 400001

National Stock Exchange of India Ltd.

Exchange plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

**Sub: Disclosure of Related Party Transactions** 

Ref: Scrip Code – BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended March 31, 2023 for your information and records.

Thanking you, Yours faithfully,

For AstraZeneca Pharma India limited

Manasa. R Company Secretary

Encl: As above

| All Figues | are in Rs Million  |   |   |  |          |   |  |  | deposits | , advances | rty transactions - applicable<br>or investments made or give,<br>during the reporting peri | en by the lis        | sted entity/ | subsidiary. T          | hese details need to be   |  |
|------------|--|---|---|--|----------|---|--|--|----------|------------|--|----------------------|--------------|------------------------|---|--|
|            | Details of the party (listed entity /subsidiary) entering into the transaction   |   | Type of related party transaction   | Value of the<br>related party<br>transaction as<br>approved by<br>the audit<br>committee | period   | In case monies are due to either party as a result of the transaction |  | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments  Details of the loans, inter-corporate deposits, advances or investments |          |            |  |                      |              |                        |   |  |
| Sr. No     | Name Name  | Relationship of the counterparty<br>with the listed entity or its<br>subsidiary |   |  |          | Opening<br>Balance as of<br>01.10.2022                                | Closing<br>Balance as of<br>31.03.2023 | Nature of indebtedness (loan / issuance of debt / any other etc.)  | Cost     | Tenure     | Nature (loan / advance /<br>inter- corporate deposit /<br>investment                       | Interest<br>Rate (%) | Lenure       | Secured /<br>unsecured | Purpose for which the<br>funds will be utilised by<br>the ultimate recipient of<br>funds (end-usage |  |
| 4          | AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom  | Fellow subsidiary   | Purchase of raw materials and stock-in-trade  |  | 1.640    | 374   | 575                                    | 4  |          |            |  |                      |              |                        |   |  |
| 2          | AstraZeneca Pharma India Limited   AstraZeneca OK Limited, United Kingdom   AstraZeneca Pharma India Limited   AstraZeneca AB. Sweden  | Fellow subsidiary   | Purchase of raw materials and stock-in-trade  |  | 384      |   |  |  |          |            |  |                      |              |                        |   |  |
|            | ASUAZENECA FINANNA INUIA LIINILEU ASUAZENECA AD, SWEUEN  | I ellow subsidiary  | r dichase of faw materials and stock-in-trade   |  | 304      | 13  | 30                                     | -  |          |            |  |                      |              |                        |   |  |
| 3          | AstraZeneca Pharma India Limited AstraZeneca Pty Ltd, Australia  | Fellow subsidiary   | Payment towards reimbursement of expenses   |  | 4        | 4   | 4                                      |  |          |            |  |                      |              |                        |   |  |
| 4          | AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom  | Fellow subsidiary   | Payment towards reimbursement of expenses   |  | 7        | -   |  |  |          |            |  |                      |              |                        |   |  |
| 5          | AstraZeneca Pharma India Limited   | Fellow subsidiary   | Payment towards employee stock compensation expense, net of withholding tax           |  | 1        |   |  |  |          |            |  |                      |              |                        |   |  |
| 6          | AstraZeneca Pharma India Limited AstraZeneca AB, Sweden  | Fellow subsidiary   | Sale of services  |  | 311      | 85  | 216                                    |  |          |            |  |                      |              |                        |   |  |
| 7          | AstraZeneca Pharma India Limited AstraZeneca UK Limited, United Kingdom  | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 75       |   |  |  |          |            |  |                      |              |                        |   |  |
| 8          | AstraZeneca Pharma India Limited AstraZeneca Singapore Pte Ltd, Singapore  | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 5        | 1   |  |  |          |            |  |                      |              |                        |   |  |
| 9          | AstraZeneca Pharma India Limited AstraZeneca Pharmaceuticals LP, USA   | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 3        | 20  | 3                                      |  |          |            |  |                      |              |                        |   |  |
| 10         | AstraZeneca Pharma India Limited AstraZeneca SDN Bhd, Malaysia   | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 5        | 2   | 6                                      |  |          |            |  |                      |              |                        |   |  |
| 11         | AstraZeneca Pharma India Limited   | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 1        | 1   | 0                                      |  |          |            |  |                      |              |                        |   |  |
| 12         | AstraZeneca Pharma India Limited AstraZeneca Canada Inc., Canada   | Fellow subsidiary   | Recovery of reimbursable expenses   |  | -        | -   | -                                      |  |          |            |  |                      |              |                        |   |  |
| 13         | AstraZeneca Pharma India Limited P.T. AstraZeneca Indonesia  | Fellow subsidiary   | Recovery of reimbursable expenses   |  | -        | -   | -                                      |  |          |            |  |                      |              |                        |   |  |
| 14         | AstraZeneca Pharma India Limited AstraZeneca India Private Limited, India  | Fellow subsidiary   | Recovery of reimbursable expenses   |  | -        | 1   |  |  |          |            |  |                      |              |                        |   |  |
| 15         | AstraZeneca Pharma India Limited AstraZeneca AB, Sweden  | Fellow subsidiary   | Recovery of reimbursable expenses   |  | -        | 59  |  |  |          |            |  |                      |              |                        |   |  |
| 16         | AstraZeneca Pharma India Limited   AstraZeneca Pharmaceuticals (Pty) Limited, South Africa   | Fellow subsidiary   | Recovery of reimbursable expenses   |  | 9        | -   | 9                                      | _  |          |            |  |                      |              |                        |   |  |
| 17         | AstraZeneca Pharma India Limited   | Fellow subsidiary Employees' Benefit Plans                                      | Recovery of reimbursable expenses  Contribution to Trusts                             |  | 14<br>30 |   | 14                                     | 4  |          |            |  |                      |              |                        |   |  |
| 10         | AstraZeneca Pharma India Limited   AstraZeneca Pharma India Limited Employees Grautity Fund Trust<br>AstraZeneca Pharma India Limited   AstraZeneca Pharma India Limited Management Staff Provident Fund Trust       |   | Contribution to Trusts  |  | 42       |   | +                                      | 4  |          |            |  |                      |              |                        |   |  |
| 20         | AstraZeneca Pharma India Limited   AstraZeneca Pharma India Limited Management Staff Superannuation Fund<br>AstraZeneca Pharma India Limited   AstraZeneca Pharma India Limited Management Staff Superannuation Fund |   | Contribution to Trusts  |  | 5        |   | +                                      | 1  |          |            |  |                      |              |                        |   |  |
| 21         | AstraZeneca Pharma India Limited Mr. Gagandeep Singh Bedi  | Former Managing Director  | Short-term employee benefits  |  | 23       |   | 1                                      | 1  |          |            |  |                      |              |                        |   |  |
| 22         | AstraZeneca Pharma India Limited Mr. Gagandeep Singh Bedi  | Former Managing Director  | Long-term employee benefits   |  | 3        |   |  |  |          |            |  |                      |              |                        |   |  |
| 23         | AstraZeneca Pharma India Limited Mr. Gagandeep Singh Bedi  | Former Managing Director  | Employee share compensation expenses  |  | 1        |   |  | 1  |          |            |  |                      |              |                        |   |  |
| 24         | AstraZeneca Pharma India Limited Mr. Gagandeep Singh Bedi  | Former Managing Director  | Post employment benefits  |  | 11       |   |  | 1  |          |            |  |                      |              |                        |   |  |
| 25         | AstraZeneca Pharma India Limited Mr. Rajesh Marwaha  | Director and Chief Financial Officer  | Short-term employee benefits  |  | 21       |   |  |  |          |            |  |                      |              |                        |   |  |
| 26         | AstraZeneca Pharma India Limited Mr. Rajesh Marwaha  | Director and Chief Financial Officer  | 3 1 7   |  | 2        |   |  |  |          |            |  |                      |              |                        |   |  |
| 27         | AstraZeneca Pharma India Limited Mr. Rajesh Marwaha  | Director and Chief Financial Officer  |   |  | 1        |   |  |  |          |            |  |                      |              |                        |   |  |
| 28         | AstraZeneca Pharma India Limited Mr. Rajesh Marwaha  | Director and Chief Financial Officer  |   |  | 1        |   | 1                                      | 1  |          |            |  |                      |              |                        |   |  |
| 29         | AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal   | Managing Director   | Short-term employee benefits  |  | 5        |   |  | 4  |          |            |  |                      |              |                        |   |  |
| 30         | AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal   | Managing Director   | Long-term employee benefits   |  | 4        |   | -                                      | 4  |          |            |  |                      |              |                        |   |  |
| 31         | AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal   | Managing Director   | Employee share compensation expenses  |  | 1        |   | -                                      | 4  |          |            |  |                      |              |                        |   |  |
| 32         | AstraZeneca Pharma India Limited Mr. Sanjeev Kumar Panchal   | Managing Director   | Post employment benefits  |  | 15       |   | 1                                      | 4  |          |            |  |                      |              |                        |   |  |
| 33         | AstraZeneca Pharma India Limited Mr. Narayan K Seshadri AstraZeneca Pharma India Limited Ms. Revathy Ashok   | Independent Directors   | Sitting fees paid to independent directors  |  | 1        | 1   | +                                      | -  |          |            |  |                      |              |                        |   |  |
| 34         | AstraZeneca Pharma India Limited   Ms. Revathy Ashok<br>AstraZeneca Pharma India Limited   Ms. Shilpa Sridhar Divekar  | Independent Directors Independent Directors                                     | Sitting fees paid to independent directors Sitting fees paid to independent directors |  | 1        | -   | +                                      | 4  |          |            |  |                      |              |                        |   |  |
| <b>3</b> 3 | ASUAZENECA FINANTIA INGIA EIMILEO (MS. STIII)PA STIGNAI DIVEKAI  | Independent Directors   | Simily rees paid to independent directors   |  | 1        | L   | 1                                      | L  |          |            |  |                      |              |                        |   |  |